Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451851 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
A Phase 3 study of Psoriasis, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT03451851 is a Phase 3 study of Psoriasis that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 120 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT03451851, a Phase 3 study of Psoriasis, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
Conditions Studied
Interventions
- DRUG Guselkumab
- DRUG Etanercept
- DRUG Placebo for guselkumab
Study Locations (20)
Other
- Eastern Health Research - Box Hill
- Royal North Shore Hospital - St Leonards
- Veracity Clinical Research - Woolloongabba
- Cliniques Universitaires Saint Luc - Brussels
- Universitair Ziekenhuis Gent - Ghent
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman - Liège
- Universitatsklinikum Bonn - Bonn
California
- Stanford University - Palo Alto
- University of California, San Diego - San Diego
Illinois
- Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's Hospital - Chicago
- Arlington Dermatology - Rolling Meadows
Texas
- Arlington Center for Dermatology - Arlington
- Dell Children's Medical Center of Central Texas - Austin
Alberta
- Kirk Barber Reseach Inc. - Calgary
- Dermatology Research Institute Inc - Calgary
Georgia
- Dermatologic Surgery Specialists - Macon
New Jersey
- Windsor Dermatology - East Windsor
New York
- Mt. Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-07-11 |
| Est. Completion | 2026-12-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03451851
The ClinicalTrials.gov registry entry for NCT03451851 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (75% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Guselkumab is the first listed.
NCT03451851 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT03451851 about?
NCT03451851 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants". The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
What is the current status of trial NCT03451851?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2018-07-11. Estimated completion is 2026-12-18.
What conditions does trial NCT03451851 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03451851?
The interventions under investigation include: Guselkumab (DRUG), Etanercept (DRUG), Placebo for guselkumab (DRUG).
Who is sponsoring clinical trial NCT03451851?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03451851 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
-
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.